trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', 'daiichi', 'astrazeneca']
enhertu has another impressive asco showing, this time in a tumor-agnostic study. but whether astrazeneca + daiichi sankyo can get a tumor-agnostic label for their her2 drug is still up in the air #asco23 
reporting on drugs and biotechs @endpts • email me: lwu@endpointsnews.com • ✌️